IgG anti Scl-70
The device SCL70.CE is an Enzyme ImmunoAssay (ELISA) intended to be used for the quantitative determination of IgG autoantibodies against Scl-70 autoantigens in human plasma and sera.
Autoimmunity is the failure of an organism to recognize its own constituent parts as self, which allows an immune response against its own cells and tissues. Any disease that results from such an aberrant immune response is termed an Autoimmune Disease.
Rheumatoid autoimmune diseases are often associated with the occurrence of autoantibodies against several nuclear or cytoplasmatic antigens. We can to distinguish between Anti Nuclear Antibodies (ANA), associate with autoimmune systemic diseases as SLE (Systemic Lupus Erythematosus), RA (Reumatoid Arthritis), Scleroderma, MCDT (Mixed Connective Tissue Disease) and Sjögren’s Syndrome; and Extractable anti Nuclear Antibodies (ENA), associate with Polymyositis, SLE, MCDT and Sjogren’s Syndrome.
Scl-70 is a extractable nuclear antigen: autoantibodies to Scl- 70 are specific to Progressive Systemic Sclerosis, a rare chronic disease characterized by diffuse fibrosis, degenerative changes and vascular abnormalities in the skin, joints and internal organs.
Anti Scl-70 are present in approximately 20-30% of such patients.
Microplates are coated with a preparation of recombinant Scl- 70 antigen. In the 1st incubation, the solid phase is treated with diluted samples and anti-SCL70 IgG are captured, if present, by the solid phase.
After washing out all the other components of the sample, in the 2nd incubation bound anti-SCL70 are detected by the addition of anti hIgG antibody, labelled with peroxidase (HRP).
The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-SCL70 IgG antibodies present in the sample. IgG in the sample may be quantitated by means of a standard curve calibrated in arbitrary units per milliliter (arbU/ml) as no international standard is available.
- Chromosoma. November 1986, Volume 94, Number 2, 0009-5915, pages 113-138. Scl 70 autoantibodies from scleroderma patients recognize a 95KDa protein identified as DNA Topoisomerase I. HH Guldner, C Szostecki, H-P Vosberg, H-J Lakomek, E Penner and F A. Bautz.
- The Journal of Rheumatology. September 2005, 32(9):1643-1649. The patogenic role of autoantibodies to nuclear autoantigens in systemic slerosis (scleroderma). JL Senecal, J Henault, Y Raymond.
- Current Rheumatology Reports. 2004, 6: 156-163. Antibodies in Scleroderma: direct pathogenicity and phenotipic associations. L Chung, MD and P J. Utz, MD.
- The Journal of Immunology. 2001, 167: 7126-7133. Systemic sclerosis (Scleroderma): specific autoantigen genes are selectively overexpressed in Scleroderma fibroblasts. X Zhou, F K. Tan, M Xiong, D M. Milewicz, C A. Feghali, M J. Fritzler, J D. Reveille and F C. Arnett.
- Rheumatology Advance. April 2009, 48(6):632-637. Redifining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA Topoisomerase I yield a specific compound immunofluorescence pattern. A Dellavance, C Gallindo, MG Soares, NP da Silva, RA Mortara and LEC Andrade.